Literature DB >> 10099836

Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain.

R S el-Bacha1, A Minn.   

Abstract

The brain is partially protected from chemical insults by a physical barrier mainly formed by the cerebral microvasculature, which prevents penetration of hydrophilic molecules in the cerebral extracellular space. This results from the presence of tight junctions joining endothelial cells, and from a low transcytotic activity in endothelial cells, inducing selective permeability properties of cerebral microvessels that characterize the blood-brain barrier. The endothelial cells provide also, as a result of their drug-metabolizing enzymes activities, a metabolic barrier against potentially penetrating lipophilic substances. It has been established that in cerebrovascular endothelial cells, several families of enzymes metabolize potentially toxic lipophilic substrates from both endogenous and exogenous origin to polar metabolites, which may not be able to penetrate further across the blood-brain barrier. Enzymes of drug metabolism present at brain interfaces devoid of blood-brain barrier, like circumventricular organs, pineal gland, and hypophysis, that are potential sites of entry for xenobiotics, display higher activities than in cerebrovascular endothelial cells, and conjugation activities are very high in the choroid plexus. Finally, xenobiotic metabolism normally results in detoxication, but also in some cases in the formation of pharmacologically active or neurotoxic products, possibly altering some blood-brain barrier properties.

Entities:  

Mesh:

Year:  1999        PMID: 10099836

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  25 in total

1.  Inhibition of rat brain microsomal cytochrome P450-dependent dealkylation activities by an oxidative stress.

Authors:  P Lagrange; R D El-Bachá; P Netter; A Minn
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

2.  Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood-brain barrier model by increasing media buffer capacity during growth.

Authors:  Hans Christian Helms; Helle Sønderby Waagepetersen; Carsten Uhd Nielsen; Birger Brodin
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

Review 3.  Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.

Authors:  Linfeng Wu; Xiaoxun Li; Dileep R Janagam; Tao L Lowe
Journal:  Pharm Res       Date:  2013-08-31       Impact factor: 4.200

Review 4.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 5.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 6.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 8.  Nanoparticle transport across the blood brain barrier.

Authors:  Andreas M Grabrucker; Barbara Ruozi; Daniela Belletti; Francesca Pederzoli; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi
Journal:  Tissue Barriers       Date:  2016-02-25

Review 9.  Sepsis-Associated Encephalopathy: The Blood-Brain Barrier and the Sphingolipid Rheostat.

Authors:  Stephen J Kuperberg; Raj Wadgaonkar
Journal:  Front Immunol       Date:  2017-06-16       Impact factor: 7.561

10.  Basic physiology of the blood-brain barrier in health and disease: a brief overview.

Authors:  Mehmet Kaya; Bulent Ahishali
Journal:  Tissue Barriers       Date:  2020-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.